3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Hodgkin Disease
2
Glioblastoma
2
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms, Plasma Cell
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemoglobinuria, Paroxysmal
1
Gliosarcoma
1
Brain Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Anemia, Aplastic
1
Interventions
Temozolomide
93
Radiotherapy
66
Bevacizumab
35
Radiation
22
Carmustine
21
Erlotinib Hydrochloride
17
Chemotherapy, Adjuvant
17
Irinotecan
16
Magnetic Resonance Spectroscopy
13
Radiotherapy, Conformal
11
O(6)-benzylguanine
11
Surgical Procedures, Operative
10
Radiotherapy, Intensity-Modulated
10
sargramostim
9
Sirolimus
9
Imatinib Mesylate
9
Carboplatin
9
temsirolimus
8
motexafin gadolinium
7
Thalidomide
7
Gene Expression Profiling
7
aldesleukin
6
Sorafenib
6
Radiosurgery
6
Immunohistochemistry
6
Hydroxyurea
6
Gefitinib
6
Filgrastim
6
Everolimus
6
Etoposide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gliosarcoma
×
Basiliximab
×
Clear all
NCT00626483
2021-03-09
REGULATe
Duke University
Phase 1
Completed
34 enrolled